Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing trick. After debuting its branded ...
AbbVie is taking a different tack in its fight with Alvotech over the Icelandic company's Humira biosimilar program, this time asking trade officials to block imports. In a recent complaint filed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback